Gilead Sciences, Inc.

Chao-I Hung

Chienhung Chou

James G Taylor

Jeromy J Cottell

Zheng-Yu Yang

Nathan E Wright

Gediminas J Brizgys

Kavoos Kolahdouzan

Elbert Chin

Rhiannon Thomas-Tran

James S Cassidy

Michael L Mitchell

Sheila M Zipfel

Scott D Schroeder

Nathan D Shapiro

Suzanne M Szewczyk

Stephen E Ammann

Daniel G Shore

Megan K Armstrong

Michael Graupe

Gregory Notte

Adam James Schrier

David W Lin

Prasenjit Kumar Mukherjee

Yifan Deng

Laurent P Debien

Ezra Roberts

Shaina V Nguyen

Joshua D Farr

Daniel Roa

Pancham Lal Gupta

Katie A Spence

Benjamin J June

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion, MTAP null, or any other MTAP deficiency. The disclosure further relates to the use of the compounds for the treatment of cancers.

PRMT5 inhibitors and uses thereof

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

Growing community of inventors

Foster City, CA, United States of America

Chao-I Hung